Introduction {#Sec1}
============

Anaerobic glycolysis is the dominant energy source during high-intensity exercise. As exercise progresses, the hydrogen ions (H^+^) that are produced when lactic acid disassociates to lactate overcome the intracellular buffering capacity and the pH of the muscle falls. The lowest muscle pH, and therefore maximum H^+^ accumulation, occurs after approximately 4 min of high-intensity exercise (Osnes and Hermansen [@CR40]), although others have suggested that H^+^ accumulation is unlikely to be the primary cause of fatigue during short duration (\<30 s) maximal exercise (Bogdanis et al. [@CR7]). Nonetheless, acidosis interferes with several metabolic processes that will result in reduced force production and fatigue (Spriet et al. [@CR49]). More specifically, the accumulation of H^+^ in the muscle has been shown to disrupt the resynthesis of phosphorylcreatine (Harris et al. [@CR18]), inhibit glycolysis (Trivedi and Daniforth [@CR58]) and disrupt the functioning of the muscle contractile machinery directly (Donaldson and Hermansen [@CR14]; Fabiato and Fabiato [@CR16]). More recent evidence also points to an effect of H^+^ accumulation in the blood on the perception of effort during high-intensity intermittent exercise (Price and Moss [@CR41]), which could also contribute to fatigue indirectly.

Physicochemical buffers in the muscle, of which carnosine is one, provide the first line of defence against local changes in pH. As such, any means of increasing the ability of the muscle to buffer the H^+^, produced during high-intensity exercise, is likely to be of value to athletes and athletic individuals. β-alanine is the rate limiting precursor to the synthesis of carnosine within muscle fibres (Ng and Marshall [@CR39]; Skaper et al. [@CR46]). Carnosine is a cytoplasmic dipeptide, which plays a role in the intracellular buffering of H^+^ due to its imidazole ring having a p*K*a of 6.83 and its high concentration (16.0 ± 7.2 to 29.2 ± 2.6 mmol kg^−1^ dm) within human skeletal muscle (Bate-Smith [@CR5]; Harris et al*.*[@CR19]; Dang et al. [@CR10]). Further support for the buffering role of carnosine in skeletal muscle comes from the higher concentrations found in fast-twitch muscle fibres (Harris et al. [@CR20]), which experience the greatest levels of H^+^ accumulation during extreme physical work. In isolated muscle, the absence of carnosine as a buffering agent leads to fatigue due to acidification, which does not occur when carnosine is present in the surrounding medium (Severin et al*.*[@CR45]).

Since muscle acidosis is likely to contribute to the onset of fatigue during high-intensity exercise, increasing the muscle carnosine concentration would theoretically increase the intracellular buffering capacity, thereby potentially delaying the onset of fatigue. Indeed, supplementation with β-alanine has been shown to significantly elevate carnosine levels in both type I and type II human muscle fibres of the *vastus lateralis* (Harris et al. [@CR21]), as well as in the *tibialis anterior*, *soleus* and *gastrocnemius* (Derave et al. [@CR12]; Baguet et al. [@CR2]; Baguet et al. [@CR3]). This provides the rationale for the ergogenic role of β-alanine supplementation on exercise that induces H^+^ formation and muscle acidosis.

This ergogenic effect of β-alanine supplementation on high-intensity exercise performance in humans has led to an expansion of the commercial market for β-alanine in recent years. There has also been a concomitant increase in interest in this research area, so much so that, since the first publication on the topic by Harris et al. ([@CR21]), there are now several comprehensive qualitative reviews on the topic of β-alanine supplementation and exercise (e.g., Artioli et al*.*[@CR1]; Derave et al*.*[@CR13]; Sale et al*.*[@CR43]).

While these reviews are undoubtedly a useful way to synthesise the available literature, such literature can also be analysed collectively in a quantitative way through meta-analysis. As such, the primary aim of this meta-analysis was to analyse the literature available on the ergogenic effect of β-alanine supplementation on exercise. The secondary aim was to investigate the outcome of the different exercise protocols employed, i.e., exercise performance and exercise capacity tests, and exercise of varying duration. This meta-analysis did not attempt to conduct a traditional qualitative review concurrently with the quantitative data presented here, and therefore readers are directed to the traditional review articles referenced above for details of the studies included in this meta-analysis.

Methods {#Sec2}
=======

Literature review and study selection {#Sec3}
-------------------------------------

The published literature was searched using the databases of PUBMED, SPORTDiscus and GoogleScholar in July 2011. A variety of combinations of words and terms were entered for the search including, but not limited to, 'beta-alanine', 'β-alanine', 'Beta Alanine', 'muscle carnosine', 'muscles', 'carnosine', 'buffering', 'exercise', 'training' and 'physical activity'. Hand searches of journal articles and of the reference lists from relevant publications were also performed to ensure, as far as practically possible, that all appropriate studies were considered for inclusion.

Once all relevant articles had been located, three researchers individually considered each article for its appropriateness for inclusion based on the pre-determined inclusion criteria discussed below. Where conflict in opinion arose the majority ruled on the inclusion or exclusion of the article. Several other desirable characteristics of studies were also discussed, such as the homogeneity of the participant population and the availability of information on the reliability of the exercise tests and measures employed, however, the inclusion criteria remained as they were.

Inclusion/exclusion criteria {#Sec4}
----------------------------

This analysis was limited to manuscripts using human participants in placebo controlled, double blinded trials, published in English language peer reviewed journals, and which had a β-alanine only supplementation group (BA) and a placebo group (Pla). Summary details of the studies included in the meta-analysis are listed in Table [1](#Tab1){ref-type="table"}. Due to these inclusion criteria, several studies were excluded from the analysis, for a multitude of reasons. These included those with no β-alanine only experimental group (Hoffman et al. [@CR27], which split participants into placebo, creatine and creatine with β-alanine groups), no exercise performance or capacity test (Smith et al*.*[@CR48]; Baguet et al. [@CR4]), an inappropriate testing strategy (Hoffman et al. [@CR28]; took baseline measurements 3 weeks after supplementation of β-alanine had commenced) or supplementation strategy (Hoffman et al. [@CR29]; used a cross-over study design with an insufficient wash out period), not published in peer reviewed journals (e.g., Hill [@CR24] and other PhD theses), or the many experiments that seem only to be available as abstracts.Table 1A summary of the studies included in the meta-analysisReferenceParticipantsExercise protocolSupplementation protocolTotal dosage (g)Effect sizeof all measures\
Median (range)Baguet et al. [@CR3]Elite rowers\
8 BA\
9 Pla2000 m rowing5 g d^−1^ for 49 days245 BA = 0.261\
Pla = −0.098Derave et al. [@CR12]Male 400 m runners\
8 BA\
7 PlaSprint running\
Isometric endurance2.4 g d^−1^ for 4 days, then 3.6 g d^−1^ for 4 days, then 4.8 g d^−1^ for 20--27 daysUp to 153.6 BA = 0.369 (0.356--0.381)\
Pla = 0.284 (0.253--0.315)Hill et al. [@CR25] (4w)Recreational males\
13 BA\
12 PlaCycle capacity at 110% power~max~4.0 g d^−1^ for 7 days, then 4.8 g d^−1^ for 7 days, then 5.6 g d^−1^ for 7 days, then 6.4 g d^−1^ for 7 days145.6 BA = 0.850 (0.720--0.980)\
Pla = 0.043 (0.012--0.074)Hill et al. [@CR25] (10w)Recreational males\
7 BA\
8 PlaCycle capacity at 110% power~max~4.0 g d^−1^ for 7 days, then 4.8 g d^−1^ for 7 days, then 5.6 g d^−1^ for 7 days, then 6.4 g d^−1^ for 49 days414.4BA = 1.046 (0.856--1.237)\
Pla = 0.105 (0.079--0.130)Jordan et al. [@CR32]Recreational males\
8 BA\
9 PlaIncremental treadmill test to exhaustion6 g d^−1^ for 28 days168 BA = 0.185 (0.041--0.189)\
Pla = 0.070 (0.053--0.098)Kendrick et al. [@CR33]Male PE students\
13 BA\
13 PlaWhole body strength\
Isokinetic force production\
Muscular endurance6.4 g d^−1^ for 70 days448BA = 0.691 (0.613--1.033)\
Pla = 0.654 (0.586--1.053)Kern and Robinson [@CR34]Male wrestlers and footballers\
17 BA\
20 PlaSprint running\
Muscular endurance4 g d^−1^ for 60 days224 BA = 0.255 (0.163--0.374)\
Pla = 0.176 (0.089--0.297)Sale et al. [@CR44]Recreational males\
10 BA\
10 PlaCycle capacity at 110% power~max~6.4 g d^−1^ for 28 days179BA = 0.964 (0.855--1.072)\
Pla = 0.104 (0.095--0.113)Smith et al. [@CR47] (3w)Recreational males\
18 BA\
18 PlaCycle capacity at 110% *V*O~2~max6 g d^−1^ for 21 days126BA = 0.600 (0.395--0.979)\
Pla = 0.607 (0.425--1.036)Smith et al. [@CR47] (6w)Recreational males\
18 BA\
18 PlaCycle capacity at 110% *V*O~2~max6 g d^−1^ for 21 days, then 3 g d^−1^ for 21 days189BA = 1.067 (0.807--1.864)\
Pla = 1.180 (0.889--1.837)Stout et al. [@CR51]Healthy males\
12 BA\
13 PlaIncremental cycle test to exhaustion6.4 g d^−1^ for 6 days, then 3.2 g d^−1^ for 22 days108.8 BA = 0.489\
Pla = −0.063Stout et al. [@CR52]Healthy females\
11 BA\
11 PlaIncremental cycle test to exhaustion3.2 g d^−1^ for 7 days, then 6.4 g d^−1^ for 21 days156.8BA = 0.217 (0.051--0.421)\
Pla = −0.023 (−0.061 to 0.006)Stout et al. [@CR53]Elderly males and females\
12 BA\
14 Pla2 min cycling bouts at ascending workloads2.4 g d^−1^ for 90 days216BA = 2.648\
Pla = −0.007Sweeney et al. [@CR55]Recreational males\
9 BA\
10 Pla2 bouts of 5 × 5 s treadmill sprints4 g d^−1^ for 7 days, then 6 g d^−1^ for 28 days196BA = 0.037 (0.003--0.072)\
Pla = 0.116 (0.065--0.191)Van Thienen et al. [@CR59]Male cyclists\
9 BA\
8 PlaIncremental cycle test to exhaustion\
Simulate cycling road race2 g d^−1^ for 14 days, then 3 g d^−1^ for 14 days, then 4 g d^−1^ for 28 days182 BA = 0.292 (0.149--0.449)\
Pla = 0.060 (−0.113 to 0.417)Walter et al. [@CR60] (3w)Recreational females\
14 BA\
19 PlaIncremental cycle test to exhaustion6 g d^−1^ for 21 days126BA = 0.953 (0.873--1.034)\
Pla = 0.537 (0.512--0.562)Walter et al. [@CR60] (6w)Recreational females\
14 BA\
19 PlaIncremental cycle test to exhaustion6 g d^−1^ for 21 days, then 3 g d^−1^ for 21 days189BA = 1.129 (1.080--1.178)\
Pla = 0.791 (0.780--0.802)Zoeller et al. [@CR62]Healthy males\
12 BA\
13 PlaIncremental cycle test to exhaustion6.4 g d^−1^ for 6 days, then 3.2 g d^−1^ for 22 days108.8BA = 0.117 (0.001--0.251)\
Pla = −0.152 (−0.456 to 0.023)

Data analysis {#Sec5}
-------------

Pre- and post-supplementation mean and standard deviations (SD) were obtained from the original data included in the published papers. Where this information was not available (Sale et al*.*[@CR44]; Derave et al*.*[@CR12]; Kern and Robinson [@CR34]) authors were contacted directly with a request for the required data. Unfortunately, further information was not received from Derave and his co-workers in relation to their data on isokinetic peak force production and, as such, this data is not included in the meta-analysis. Where standard error of the mean (SEM) rather than standard deviation was reported, this was calculated as $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\text{SD}} = {\text{SEM}} \times \sqrt n , $$\end{document}$ where *n* is the group sample size. The effectiveness of the supplementation (for BA and Pla groups) was quantified by calculating the effect size, which is the difference between the pre- and post-supplementation measures, divided by the pooled SD of the two occasions. Therefore, effect size represents a common measure of treatment effectiveness, which allows the findings of individual studies to be analysed together. Where a smaller number represents a better result (such as running performance), the subtraction is reversed and thus a positive effect size still represents a positive treatment effect. Each effect size was then corrected to adjust for any positive bias due to small sample size (Thomas and French [@CR57]). The studies of Hill et al. ([@CR25]), Smith et al. ([@CR47]) and Walter et al*.* ([@CR60]) reported dose and exercise data pre-, mid- and post-supplementation, allowing each of these studies to be subdivided into two separate protocols, i.e., pre- to mid-supplementation data and pre- to post-supplementation data.

Classifying of variables {#Sec6}
------------------------

Exercise measures were analysed as one complete group for the overall effect of β-alanine supplementation compared to a placebo. Due to the mechanisms by which β-alanine is proposed to have an ergogenic effect on exercise, the data were then sub-divided.

Where possible, data were separated into those generated by exercise capacity and exercise performance tests. Exercise capacity tests require the participant to exert themselves to the point of volitional exhaustion, rather than to a fixed end point as is the case in exercise performance tests, therefore capacity tests are usefully employed when a maximal production of H^+^ is desired. Although exercise performance tests are deemed to have a greater level of ecological validity, they rely upon intrinsic pacing strategies which may not elicit optimal performance (Hinckson and Hopkins [@CR26]). If there is no fixed pacing strategy, as may be the case in sub-elite athletes, then the effects of an intervention might be masked by large variance; if there is a fixed pacing strategy, as may be the case in elite or experienced athletes, it may not allow the effects of an intervention to be shown. Therefore, exercise capacity and exercise performance data were analysed separately.

Measures were also sub-divided by exercise duration, given that β-alanine supplementation increases carnosine concentrations in skeletal muscle and acts indirectly to increase muscle buffering capacity. During exercise of less than 60 s duration, H^+^ accumulation is unlikely to be sufficient to be the primary cause of fatigue as Bogdanis et al. ([@CR7]) showed that a reduced muscle pH, induced by sprint exercise prior to the test, did not affect performance of a single bout of 30 s maximal cycling. Maximum H^+^ accumulation occurs after approximately 4 min of high-intensity exercise, as Osnes and Hermansen ([@CR40]) demonstrated with greatest blood lactate values and lowest blood pH values seen after running 1,500 m (3 min 48 s) compared to distances ranging from 100 to 5,000 m. Therefore, the tests included in this meta-analysis were subdivided into those lasting \<60 s, 60--240 s and \>240 s.

Finally, the dose of β-alanine administered (above or below the average daily and total dose, as determined by mean and median) was also investigated to determine if there was a direct link between the dose and the effect of β-alanine. Information regarding which tests were included in each grouping is available in Table [2](#Tab2){ref-type="table"}*.*Table 2A summary of the studies and measures included in the sub-sections of the meta-analysisReferenceTestMeasureC/P1/2/3Baguet et al. [@CR3]2,000 m rowing2,000 m rowing timeP3Derave et al*.*[@CR12]Sprint running\
Isometric endurance@ 45% MVC400 m running timeP1Isometric contraction time to exhaustionC2Hill et al*.*[@CR25](4w)Cycle capacity at 110% power~max~Total work doneC2Cycle time to exhaustionC2Hill et al*.*[@CR25] (10w)Cycle capacity at 110% power~max~Total work doneC2Cycle time to exhaustionC2Jordan et al*.*[@CR32]Incremental treadmill test to exhaustion*V*O~2~maxC3*V*O~2~ at OBLA3%*V*O~2~max at OBLA3Heart rate at OBLA3%Heart rate max at OBLA3Kendrick et al. [@CR33]Whole body strength\
Isokinetic force production\
Muscular enduranceCumulative box squat, bench press and dead liftP1Isokinetic force productionP1Upper arm curl repetitions to exhaustionC1Kern and Robinson [@CR34]Sprint running\
Muscular enduranceWrestlers 300 yd shuttle run timeP2Footballers 300 yd shuttle run timeP1Wrestlers 90° flexed-arm hangC2Footballers 90° flexed-arm hangC1Sale et al*.*[@CR44]Cycle capacity at 110% Power~max~Total work doneC2Cycle time to exhaustionC2Smith et al. [@CR47](3w)Cycle capacity at 110% *V*O~2~peakTotal work doneC3Cycle time to exhaustionC3*V*O~2~peakC3Ventilatory threshold3Smith et al. [@CR47] (6w)Cycle capacity at 110% *V*O~2~peakTotal work doneC3Cycle time to exhaustionC3*V*O~2~peakC3Ventilatory threshold3Stout et al*.*[@CR51]Incremental cycle test to exhaustionPhysical work capacity at fatigue thresholdC3Stout et al*.*[@CR52]Incremental cycle test to exhaustionPhysical work capacity at fatigue thresholdC3Cycle time to exhaustionC3*V*O~2~peakC3Ventilatory threshold3Stout et al*.*[@CR53]2 min cycling bouts at ascending workloadsPhysical work capacity at fatigue thresholdC3Sweeney et al*.*[@CR55]2 bouts of 5 × 5 s treadmill sprintsHorizontal power (mean)%P1Horizontal power (peak)%P1Performance decrease (mean)1Performance decrease (peak)1van Thienen et al*.*[@CR59]Incremental cycle test to exhaustion\
Simulated cycling road raceTime to exhaustionC3Mean power output in 10 min time trialP3Peak power output in 30 s sprintP1Mean power output in 30 s sprintP1Final power output in 30 s sprintP1% Fatigue in 30 s sprint1Walter et al*.*[@CR60] (3w)Incremental cycle test to exhaustion*V*O~2~peakC3Power output at ventilatory threshold3Walter et al. [@CR60] (6w)Incremental cycle test to exhaustion*V*O~2~peakC3Power output at ventilatory threshold3Zoeller et al. [@CR62]Incremental cycle test to exhaustionTime to exhaustionC3*V*O~2~peakC3*V*O~2~ at ventilatory threshold3%*V*O~2~peak at ventilatory threshold3Power output at ventilatory threshold3*V*O~2~ at lactate threshold3%*V*O~2~peak at lactate threshold3Power output at lactate threshold3P indicates that the measure was included in the exercise performance analysis, C indicates that the measure was included in the exercise capacity analysis, 1 indicates that the measure was included in the \<60 s exercise duration analysis, 2 indicates that the measure was included in the 60--240 s exercise duration analysis, 3 indicates that the measure was included in the \>240 s exercise duration analysis*OBLA* onset of blood lactate accumulation, *MVC* maximum voluntary contraction

Statistical analysis {#Sec7}
--------------------

With the data divided as BA and Pla groups, and the number of effect sizes in each group dictated by the variable being investigated, the data were analysed for skewness, kurtosis and normality of distribution. In all cases, the data were not normally distributed, and therefore independent samples Mann--Whitney *U* tests and Spearman's correlation coefficients were employed using SPSS version 18. Data are presented as median (interquartile range) unless otherwise stated and statistical significance was accepted at *P* ≤ 0.05.

Results {#Sec8}
=======

Studies {#Sec9}
-------

Fifteen published investigations met the inclusion criteria (see Table [1](#Tab1){ref-type="table"} for study details). Several studies employed multiple exercise tests and multiple measures within those tests, therefore 57 effect sizes were calculated for inclusion in the analysis. A total of 360 participants were included, subdividing into 174 participants in the BA group and 186 participants in the Pla group; the average group size was 12 participants, with a range of 7--20 participants. Of the 360 participants, 20.3% were female and 7.2% were elderly males and females (range 55--92 years), but the vast majority of participants (77.2%) were young, healthy, active males. Of the 15 studies included in the meta-analysis, 8 acknowledge the donation of the supplement used from a commercial company and 3 state the brand of supplement used, but 4 studies make no reference as to the source of the β-alanine administered (Stout et al*.*[@CR51]; Zoeller et al*.*[@CR62]; Smith et al. [@CR47]; Walter et al. [@CR60]). Furthermore, five manuscripts acknowledge an element of financial support for their study from a commercial company (Hill et al. [@CR25]; Smith et al. [@CR47]; Zoeller et al. [@CR62]; Stout et al. [@CR51]; Jordan et al. [@CR32]).

Overall {#Sec10}
-------

The effect size of the Pla group was 0.108 (−0.019 to 0.487) and the effect size of the BA group was 0.374 (0.140--0.747). This equated to a significant effect of β-alanine supplementation compared to a placebo (*P* = 0.002). Further data analysis indicates that supplementation with a total of 179 g of β-alanine (the median dose across all studies) would result in a median improvement of 2.85% compared with a placebo.

Exercise performance and capacity {#Sec11}
---------------------------------

Twelve exercise performance measures were employed in six studies (see Table [2](#Tab2){ref-type="table"} for details). When combined, tests such as rowing performance (Baguet et al. [@CR3]), running performance (Derave et al. [@CR12]; Kern and Robinson [@CR34]) and maximal strength tests (Kendrick et al*.*[@CR33]) had an effect size of 0.150 (−0.059 to 0.473) in the Pla group and 0.326 (0.164--0.549) in the BA group, although this was not significantly different (*P* = 0.204; Fig*.*[1](#Fig1){ref-type="fig"}).Fig. 1The effect size of Pla and BA groups when subdivided by type of exercise test or measure. *Light grey* represents Pla groups and *dark grey* represents BA groups. \* denotes significantly greater than Pla (*P* = 0.013)

However, there was a significant difference between BA and Pla groups when exercise capacity was assessed (*P* = 0.013). Thirteen of the fifteen studies included in this meta-analysis employed a total of 27 exercise capacity measures to investigate the effects of β-alanine supplementation. BA groups had an effect size of 0.591 (0.341--1.071) while the Pla groups had a smaller effect size of 0.156 (0.040--0.566; Fig. [1](#Fig1){ref-type="fig"}).

Exercise durations {#Sec12}
------------------

The 57 exercise measures included in this meta-analysis were also divided into those lasting \<60 s, 60--240 s and \>240 s (see Table [2](#Tab2){ref-type="table"} for details). For the 14 measures lasting \<60 s there was no significant difference between the effect sizes in the BA and Pla groups \[0.193 (0.072--0.540) and 0.118 (−0.037 to 0.471); *P* = 0.312\]. For the 9 measures lasting 60--240 s there was a significant difference between the effect size of the BA and Pla groups \[0.665 (0.481--1.110) and 0.121 (0.087--0.221); *P* = 0.001\]. However, once exercise duration increased over 240 s the beneficial effects of β-alanine supplementation from the 34 measures become less pronounced, although still significant \[BA 0.368 (0.133--0.797), Pla 0.095 (−0.059 to 0.607); *P* = 0.046\]. Figure [2](#Fig2){ref-type="fig"} demonstrates this pattern.Fig. 2The effect size of Pla and BA groups when subdivided by exercise duration. *Light grey* represents Pla groups and *dark grey* represents BA groups. \* denotes significantly greater than Pla (*P* = 0.046), \*\*\* denotes significantly greater than Pla (*P* = 0.001)

Dosage {#Sec13}
------

A large variety of supplementation protocols were employed, meaning that the total amount of β-alanine ingested by each participant varied from 108.8 (Stout et al*.*[@CR51]; Zoeller et al*.*[@CR62]) to 448 g (Kendrick et al*.*[@CR33]), the daily dosage varied from 2.4 (Stout et al. [@CR53]) to 6.4 g d^−1^ (Sale et al. [@CR44]; Kendrick et al. [@CR33]) and the individual maximum dosage administered varied from 800 to 2,000 mg, although Smith et al. ([@CR47]) and Jordan et al. ([@CR32]) do not provide this information. The effect size of the dosage administered (total and g d^−1^) was analysed as those above and below the median dose \[total dose 179 g (126--196 g); daily dose 5.12 g d^−1^ (4.10--5.98 g d^−1^)\] when all studies were taken together. There was no relationship between the dose of β-alanine administered and the difference between the effect size of the BA and Pla groups seen in the exercise measures (*P* = 0.337). The difference in the median effect size between the BA and Pla groups for each study is plotted in relation to the total dose of β-alanine supplemented in Fig. [3](#Fig3){ref-type="fig"}. Through regression analysis, the data of Stout et al*.* ([@CR53]; data point 13 in Fig. [3](#Fig3){ref-type="fig"}) were shown to have a standard residual value of 3.54, indicating that it may be an outlier. However, it's exclusion from the analysis did not result in a relationship between dose and effect size difference, and therefore this study remained in the meta-analysis.Fig. 3The difference in the median effect size of the BA and Pla groups of each study in relation to the total dose of β-alanine supplemented

Discussion {#Sec14}
==========

To our knowledge, this is the first meta-analysis to be published on this topic and it shows that there is a significant effect of β-alanine supplementation on all exercise measures when taken as a single group. Analysis indicates that supplementation with a total of 179 g of β-alanine (the median dose across all studies) would result in a median improvement of 2.85% compared with a placebo. Assuming a linear relationship between running speed and percentage effect, if this improvement was extrapolated and applied to a sporting event lasting around 4 min, such as a 1,500 m run, performance time would be improved by \~6 s. This improvement would be sufficient to move the last place finalist in the men's 1,500 m at the Beijing 2008 Olympic games to a bronze medal position. It should be noted that this calculation is based upon the median effect across several studies, and the vast majority of participants in the studies of this meta-analysis are recreationally active individuals rather than elite athletes. Furthermore, this meta-analysis has shown, from the data available to date, that β-alanine supplementation does not result in an improvement in performance-based measures, although the number of performance tests conducted on β-alanine supplementation is comparatively few (*n* = 12). Of these, only one (300 yard shuttle run; Kern and Robinson [@CR34]) falls within the time frame in which β-alanine supplementation is most efficacious (60--240 s). Currently only one exercise test (the cycling capacity test at 110% power max) has been repeated with different subjects taking β-alanine (Hill et al. [@CR25]; Sale et al. [@CR44]). These studies have shown that, with 145.6 and 179 g of β-alanine, exercise capacity (time to exhaustion) was improved by 11.8 and 12.1% (Hill et al*.*[@CR25]; Sale et al. [@CR44]). Therefore, given the potential demonstrated for significant improvements in exercise lasting 60--240 s, this meta-analysis highlights the need for more studies investigating the effects of β-alanine supplementation on exercise performance of this duration.

Performance/Capacity {#Sec15}
--------------------

β-alanine supplementation improves exercise capacity (*P* = 0.013), with BA showing a 'moderate' effect size compared to Pla (Cohen [@CR8]). However, to date, the available data suggests that β-alanine supplementation has no benefit on measures of exercise performance rather than exercise capacity. This result is perhaps unsurprising as only 2 of the 12 performance measures included in the meta-analysis have shown a significant difference between the BA and Pla groups (mean power output and peak power output in a 30 s cycle sprint, after 125 min of previous cycling; Van Thienen et al*.*[@CR59]), although a third test reported a strong trend (*P* = 0.07) for an improvement in the supplemented group (2,000 m rowing; Baguet et al. [@CR3]). Many of the tests and measures employed showed improvements in both groups, which could be due to a potential 'placebo effect', or possibly a greater participant understanding of how to perform the trial (Laursen et al*.*[@CR36]). However, this is unlikely to be the true explanation for the results seen here as 3 of the 6 studies conducted full familiarisation trials with the participants prior to testing (Kendrick et al*.*[@CR33]; Sweeney et al*.*[@CR55]; van Thienen et al. [@CR59]), and the other three studies employed tests with which the participants were already fully familiar (Derave et al*.*[@CR12]; Baguet et al. [@CR3]; Kern and Robinson [@CR34]).

Although it can be argued that performance tests are more ecologically valid (Coyle et al. [@CR9]), they require pacing strategies to be employed, which may be a confounding factor (Hinckson and Hopkins [@CR26]). Exercise capacity tests do not require this skill and are often of more use in exercise physiology research, where mechanistic investigations are often the focus rather than the artificial recreation of a sporting setting. Furthermore, exercise capacity tests are, by their very nature, maximal and will, therefore maximally stress the homeostasis of the internal environment. Exercise performance tests may not be maximal due to the use of pacing strategies, be these consistent strategies which mask the effect of an intervention, or inconsistent strategies which increase variability. It is possible that differences in the efficacy of β-alanine supplementation between performance and capacity tests and measures exist due to these factors.

Exercise intensity and duration {#Sec16}
-------------------------------

Currently it would seem likely that the main ergogenic mechanism by which β-alanine acts is through an elevation in carnosine synthesis within the muscle (Harris et al. [@CR21]), which in turn buffers the H^+^ accumulation that occurs during high-intensity exercise (Hill et al*.*[@CR25]). There are other proposed mechanisms by which β-alanine supplementation can influence exercise performance, namely through acting as a sacrificial peptide to protect against glycation, acting as an anti-oxidant and/or increasing calcium sensitivity in contractile fibres. Readers are directed to the review articles of Sale et al. ([@CR43]) and Derave et al. ([@CR13]) for more detailed discussion of these possibilities. The data in this meta-analysis clearly shows that exercise of a duration less than 60 s is not improved by β-alanine supplementation, while exercise of 60--240 s clearly is improved, and exercise over 240 s is also improved, although to a lesser extent.

The data presented here provide further evidence of the ergogenic effects of β-alanine supplementation to augment the intramuscular buffering of H^+^, which accumulate during high-intensity exercise lasting 1--4 min, a period when anaerobic energy sources can contribute between 20 and 60% of the total energy requirement (Maughan et al. [@CR37]). The cause of fatigue in exercise of less than 60 s is unlikely to be an extreme acidosis and more likely to be due to the gradual decline in anaerobic ATP production and/or an increase in ADP accumulation, and therefore the increased ability of the muscle to buffer H^+^ is unlikely to be fully utilised. However, it should be noted that, despite previous research suggesting that a reduced muscle pH did not affect performance of a single bout of 30 s maximal cycling (Bogdanis et al*.*[@CR7]), Suzuki et al. ([@CR54]) showed a positive correlation between muscle carnosine concentration and power output towards the end of a 30 s maximal cycling bout. Therefore, it is likely that the relationship shown by Suzuki et al. ([@CR54]) between carnosine concentrations and exercise performance followed from the significant correlation also observed between carnosine and muscle fibre type. It is possible that, the area occupied by type II muscle fibres was more important to 30 s maximal sprint cycling than pH regulation directly. This meta-analysis supports the findings of Bogdanis et al. ([@CR7]) that muscle buffer capacity does not affect performance during very short duration (\<60 s) exercise.

Of interest are the data generated relating to exercise lasting over 240 s as here, H^+^ accumulation and muscle lactate concentrations are still likely to be high, but the increasing involvement of aerobic metabolism will not increase the acidosis in the muscle further. Therefore, other pathways related to β-alanine supplementation and the role of carnosine in the muscle, such as an effect of β-alanine on delaying the fatigue induced increase in ventilation rate (Stout et al. [@CR52]), may be the mechanism behind this ergogenic effect. Unfortunately, many of the papers employing exercise lasting \>240 s did not report the exact exercise duration. Therefore, it was not possible to normalise these data for their duration, which would have allowed us to examine if a relationship existed between β-alanine supplementation and exercise duration \>240 s. As such, the effects of β-alanine on exercise \>240 s warrants further research.

β-alanine dosage {#Sec17}
----------------

Stellingwerff ([@CR50]) recently published findings which demonstrate that as the dose of β-alanine supplemented increases, the duration of supplementation required to elicit changes in the muscle carnosine content is reduced. There is currently no known threshold to the storage of carnosine in muscle and therefore it would seem logical that the more β-alanine that is supplemented, be that at a lower dose over a longer duration or at a higher dose over a shorter duration, the more carnosine can be synthesised and stored in the muscle. This could lead to a greater muscle buffering capacity during high-intensity exercise and therefore an improvement in exercise outcomes. Indeed, this theory is partially supported by the data of Hill et al. ([@CR25]) in which total work done during a cycling capacity test increased by 13% after 4 weeks and a further 3.2% after 10 weeks of β-alanine supplementation, with no changes shown in the control group. Hill et al*.* ([@CR25]) demonstrated a continuing improvement in exercise outcome with increased amounts of β-alanine ingested, although the relationship was not linear.

However, what this meta-analysis suggests is that the dose of β-alanine supplemented, and therefore presumably the magnitude of the change in muscle carnosine content, does not influence the outcome of exercise measures. When the difference in the effect size of the BA and Pla groups for each measure is compared across studies, there does not appear to be a relationship between the dose of β-alanine supplemented and median effect size of all the measures at that dose. Sweeney et al. ([@CR55]) had the smallest median effect size difference \[−0.027 (−0.136 to 0.007)\] but one of the larger total doses of β-alanine supplemented (196 g). Similarly, Kendrick et al. ([@CR33]) used the greatest dose of β-alanine, but had one of the smaller median effect size differences \[0.018 (−0.029 to 0.027)\]. The data of Stout et al*.* ([@CR53]) had a standard residual value of 3.54, indicating that it may be an outlier. However, this data was not removed from the analysis as presently the shape of the dose--response curve for β-alanine supplementation is unknown. Unfortunately, due to many different tests and measures performed in the β-alanine supplementation studies to date, which do not always focus on H^+^ accumulation (as discussed above), and the use of different dosing strategies, it remains unclear whether there is a direct link between the dose of β-alanine supplemented and the exercise outcome. Indeed, where large doses of β-alanine were supplemented, but only small differences in effect size were shown between BA and Pla groups, this could be due to the exercise test or measure employed, rather than the supplementation dose. This is a potential avenue for future research.

Potential confounding factors of β-alanine research studies {#Sec18}
-----------------------------------------------------------

Research has shown that, in commercially available supplementation products, there is a substantial chance of contamination with banned substances and/or different concentrations of ingredients to those listed on the supplement container (Geyer et al*.*[@CR17]). It is also possible that supplements contain other substances which may interfere with the uptake of the target compound, as in vitro tests have shown with taurine and β-alanine (Jessen [@CR30]). Several studies included in this meta-analysis have used commercially available supplements, the purity of which does not appear to have been tested and/or reported. As such, future investigations should make every attempt to ensure the purity of the supplement used through independent analysis of the product. Where such efforts have been made, this should be included in the manuscript \[see Sale et al*.* ([@CR44]) and Stout et al*.* ([@CR51]) for examples of good practice\], allowing the reader to have full confidence in the data reported.

β-alanine causes paraesthesia in some individuals (Harris et al. [@CR21]), a side effect which ethically should be included in participant information sheets issued to prior to participation in all studies. It would therefore be clear to any participant suffering from paraesthesia that they were on the active treatment rather than the placebo, effectively removing the blinding of the study. Therefore, particularly with exercise based investigations, the results may no longer be valid. Theoretically, any individual reporting paraesthesia should be excluded from the study and replacement participants should be recruited, although this rarely seems to occur or at least is rarely reported. As such, this is something that should be considered in future β-alanine studies. Indeed, the advent of new 'slow-release' formulations of β-alanine are working to address this potentially confounding factor (Harris et al*.*[@CR22]), and Sale et al*.* ([@CR44]) have recently used this formulation and report no symptoms of paraesthesia in their participants. Subsequently, Decombaz et al. ([@CR11]) showed that ingesting 1.6 g of BA in the form of slow-release tablets resulted in no more sensory side effects than a placebo supplement and significantly less than when the same dose of BA was administered in pure solution.

The washout period for β-alanine has been shown to be 15 weeks or longer (Baguet et al*.*[@CR2]; Stellingwerff ([@CR50])). Studies must therefore ensure that all participants have been free from supplementation for a minimum of almost 4 months before participating in a β-alanine research study. Furthermore, this extensive washout period means that cross-over design studies in the field of β-alanine supplementation are unlikely to be possible, since a participants' fitness levels and dietary patterns might be expected to change over this duration.

Training programmes incorporated into some studies (Smith et al. [@CR47]; Walter et al. [@CR60]; Kendrick et al*.*[@CR33]) may be a confounding factor or might mask the effects of β-alanine. Although intracellular pH buffering has received much of the attention, several other mechanisms for the ergogenic effect of β-alanine supplementation have been proposed. These include the increase in Ca^2+^ sensitivity of the contractile fibres caused by elevated carnosine concentrations allowing the maintenance force production in the later stages of fatigue when Ca^2+^ release normally declines (Dutka and Lamb [@CR15]), or the potential antioxidant effects of carnosine delaying the onset of fatigue during intense and prolonged exercise through the inhibition of Ca^2+^ sensitivity (Reid [@CR42]). Therefore, while the area of β-alanine research is in its relative infancy, it might be more prudent to focus research efforts into confirming the mechanism or mechanisms by which β-alanine supplementation has an ergogenic effect.

Within sports science research, exercise tests are one of the most commonly used tools (Hinckson and Hopkins [@CR26]), and a large variety of exercise tests and measures have been used to assess the efficacy of β-alanine supplementation. It has been suggested that exercise capacity tests have poor reliability when compared to performance tests (26.6% CV compared to 3.4% CV, Jeukendrup et al*.*[@CR31]), although several authors have shown that, when participants have been well familiarised and tests are rigorously standardised and executed, exercise capacity tests can also have good levels of reliability (e.g., 4.4%, Sale et al. [@CR44]; 3%, Watson et al*.*[@CR61]). Unfortunately, the reliability of tests and measures employed are rarely reported, meaning that the significance of any alteration in exercise capacity or performance with β-alanine supplementation cannot be accurately interpreted. Authors should report the reliability of their exercise tests and measures in the manuscript to allow the reader to interpret the results in view of the sensitivity of the test or measure employed.

Another confounding factor applicable to all sports science research is the potential for studies to be under-powered, possibly through a lack/manipulation of the sample size estimation (Batterham and Atkinson [@CR6]). This may be the case in some investigations presented here due to the large variance in participant numbers (*n* = 7, Derave et al*.*[@CR12]; *n* = 20, Kern and Robinson [@CR34]). Unfortunately however, retrospective power analysis calculated using effect size and variance is of limited use (Thomas [@CR56]). Meta-analysis aims to partially address the imbalance of influence that studies with small sample sizes have (Hedges [@CR23]) by correcting the effect size prior to averaging through the application of a correction factor leading to a virtually unbiased estimate of effect size (Thomas and French [@CR57]).

Finally, care should be taken when generalising these findings to special populations, such as female athletes or elderly individuals. Only 3 of the 15 studies included female participants, and all of these studies employed exercise tests or measures lasting \>240 s, where the effects of β-alanine supplementation were less pronounced than in the 60--240 s exercise duration group. Further, only 1 of the 15 studies included elderly participants, and this study also used an exercise testing protocol of \>240 s.

Limitations of meta-analysis as a research technique {#Sec19}
----------------------------------------------------

During a meta-analysis, studies with critical flaws in the methodology can be omitted from the analysis at the outset. However, meta-analysis does not allow the methodological quality of the studies included in the analysis to be taken into account in the reporting and interpretation of the results. Moja et al*.* ([@CR38]) suggests that, while even such gold standard review bodies as The Cochrane Reviews may fare well in the assessment of methodological quality of primary studies, they largely fail to take this into account in the interpretation of the results. It would seem that the establishment of a technique to allow the assessment of the methodological quality of individual studies, and therefore potentially weight their findings accordingly, is still underdeveloped, meaning there is still substantial room for future improvement in the meta-analytical technique.

As a widely acknowledged rule of thumb, it is easier to get positive findings published in peer reviewed journals than findings of a negative or no effect (Kirkwood and Sterne [@CR35]). Therefore, when conducting any review, particularly a meta-analysis, there is a risk of bias in the findings towards a positive effect of an intervention. However, studies into β-alanine supplementation that have not shown a positive effect have been published (Zoeller et al. [@CR62]; Walter et al. [@CR60]; Kern and Robinson [@CR34]; Sweeney et al*.*[@CR55]; Kendrick et al. [@CR33]; Baguet et al. [@CR3]), suggesting that this research field may not yet be tainted by publication bias to the same extent as others, although the extent of publication bias in a research field is difficult to estimate.

Conclusion and recommendations {#Sec20}
==============================

The median overall effect of β-alanine supplementation is a 2.85% (−0.37 to 10.49%) improvement in the outcome of an exercise measure, when 179 g of β-alanine is supplemented; although this value is likely to change dependent upon a variety of factors. In the only test to be repeated following 4 weeks of β-alanine supplementation across two different studies, increases in exercise capacity were indeed outside this range at 11.8% (Hill et al. [@CR25]) and 12.1% (Sale et al. [@CR44]). From the data available to date, it can be concluded that β-alanine supplementation elicits a significant ergogenic effect on high-intensity exercise, particularly in exercise capacity tests and measures, and where the exercise lasts between 1 and 4 min. Areas which warrant further investigation due to the borderline efficacy of β-alanine, i.e., exercise lasting over 240 s, have also been highlighted. This meta-analysis has shown that exercise performance tests and measures, and exercise of less than 60 s duration are not improved by β-alanine supplementation. Given the types, intensities and durations of exercise positively influenced by β-alanine supplementation, we maintain that the most likely mechanism supporting a benefit is through an increase in intracellular pH buffering as the result of increased muscle carnosine levels.

The diversity of the methodologies used in the assessment of the efficacy of β-alanine highlights the importance of clear logical progression through the different aspects of supplementation to eventually be able to produce a clear concise set of criteria for its efficacy. Authors should also make every attempt to demonstrate: the purity of the supplement used; the double blinding of the treatments; and the reliability of the exercise tests or measure employed. It would also be of interest to investigate if a link exists between dose of β-alanine administered, the degree of elevation in muscle carnosine content and the magnitude of the improvement in an exercise outcome. However, this area of research is still in its infancy and therefore any well conducted, double-blinded, randomised control trials with a good rationale should continue to be conducted.
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